

# Paola Rogliani

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1341783/paola-rogliani-publications-by-citations.pdf>

**Version:** 2023-06-07

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

341  
papers

6,130  
citations

38  
h-index

63  
g-index

371  
ext. papers

7,552  
ext. citations

4.6  
avg, IF

6.42  
L-index

| #   | Paper  | IF  | Citations |
|-----|--|-----|-----------|
| 341 | Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 2832-5 | 3.3 | 453       |
| 340 | Feasibility and results of awake thoroscopic resection of solitary pulmonary nodules. <i>Annals of Thoracic Surgery</i> , <b>2004</b> , 78, 1761-8   | 0.5 | 189       |
| 339 | β-agonist therapy in lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 690-6  | 2.5 | 179       |
| 338 | A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. <i>Chest</i> , <b>2016</b> , 149, 1181-96  | 1.2 | 160       |
| 337 | Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 101-9  | 2.9 | 143       |
| 336 | Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , <b>2015</b> , 24, 451-61  | 2.3 | 112       |
| 335 | Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , <b>2017</b> , 124, 6-14   | 1.2 | 97        |
| 334 | Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. <i>Brain, Behavior, and Immunity</i> , <b>2020</b> , 88, 11-16   | 4.4 | 95        |
| 333 | The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. <i>Respiratory Medicine</i> , <b>2016</b> , 117, 190-7   | 1.2 | 95        |
| 332 | Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2012</b> , 143, 47-54, 54.e1   | 0.3 | 86        |
| 331 | Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 40, 95-103  | 0.8 | 80        |
| 330 | Triple therapy single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , <b>2018</b> , 52,  | 2.9 | 78        |
| 329 | HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. <i>Hla</i> , <b>2020</b> , 96, 610-614  | 0.5 | 76        |
| 328 | Asthma and comorbid medical illness. <i>European Respiratory Journal</i> , <b>2011</b> , 38, 42-9  | 2.9 | 75        |
| 327 | Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. <i>European Journal of Pharmacology</i> , <b>2014</b> , 745, 135-43  | 1.6 | 71        |
| 326 | Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. <i>Respiratory Medicine</i> , <b>2012</b> , 106, 249-56   | 1.2 | 71        |
| 325 | Awake thoroscopic biopsy of interstitial lung disease. <i>Annals of Thoracic Surgery</i> , <b>2013</b> , 95, 445-52  | 0.5 | 69        |

|     |   |     |    |
|-----|---|-----|----|
| 324 | Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2013</b> , 346, 414-23                                     | 1.1 | 67 |
| 323 | Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 552-563  | 0.5 | 61 |
| 322 | Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2015</b> , 12, 175-81  | 0.5 | 59 |
| 321 | Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>1999</b> , 20, 441-7     | 1.5 | 58 |
| 320 | Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , <b>2016</b> , 17, 70 | 1.8 | 58 |
| 319 | Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. <i>Chest</i> , <b>2019</b> , 155, 758-770   | 1.2 | 56 |
| 318 | High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2012</b> , 47, 509-16  | 1.5 | 51 |
| 317 | Effect of lung volume reduction surgery for severe emphysema on right ventricular function. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 165, 489-94   | 2.5 | 51 |
| 316 | Pharmacology and Therapeutics of Bronchodilators Revisited. <i>Pharmacological Reviews</i> , <b>2020</b> , 72, 218-257  | 1.2 | 49 |
| 315 | COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells. <i>Genes</i> , <b>2020</b> , 11,   | 1.2 | 48 |
| 314 | Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome?. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 977-983  | 3   | 47 |
| 313 | Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 31, 15-27  | 0.8 | 47 |
| 312 | HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. <i>Respiratory Medicine</i> , <b>2008</b> , 102, 1753-61   | 1.2 | 46 |
| 311 | Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 148-158  | 0.8 | 45 |
| 310 | Searching for the synergistic effect between acclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1305-11  | 1.2 | 44 |
| 309 | LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , <b>2017</b> , 26,   | 2.3 | 43 |
| 308 | Brain natriuretic peptide: Much more than a biomarker. <i>International Journal of Cardiology</i> , <b>2016</b> , 221, 1031-8   | 0.8 | 42 |
| 307 | Comorbidities of asthma: current knowledge and future research needs. <i>Current Opinion in Pulmonary Medicine</i> , <b>2013</b> , 19, 36-41  | 1.1 | 42 |

|     |  |     |    |
|-----|--|-----|----|
| 306 | Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1133-46   | 0.9 | 39 |
| 305 | Defining phenotypes in COPD: an aid to personalized healthcare. <i>Molecular Diagnosis and Therapy</i> , <b>2014</b> , 18, 381-8   | 1.3 | 38 |
| 304 | Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , <b>2017</b> , 129, 189-198   | 1.2 | 38 |
| 303 | Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2011</b> , 24, 221-6   | 0.8 | 38 |
| 302 | Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. <i>Respiratory Research</i> , <b>2017</b> , 18, 26  | 1.8 | 37 |
| 301 | Adherence to COPD treatment: Myth and reality. <i>Respiratory Medicine</i> , <b>2017</b> , 129, 117-123  | 1.2 | 37 |
| 300 | Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 32, 15-23 | 0.8 | 37 |
| 299 | Biomarkers of lung damage associated with tobacco smoke in induced sputum. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 1592-613   | 1.2 | 37 |
| 298 | Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 36, 1-9  | 0.8 | 35 |
| 297 | Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. <i>Radiology</i> , <b>2010</b> , 254, 601-8   | 4.7 | 33 |
| 296 | Airflow obstruction: is it asthma or is it COPD?. <i>International Journal of COPD</i> , <b>2016</b> , 11, 3007-3013   | 0.8 | 33 |
| 295 | Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. <i>BMC Pulmonary Medicine</i> , <b>2018</b> , 18, 70  | 1   | 32 |
| 294 | The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2013</b> , 26, 325-31  | 0.8 | 32 |
| 293 | Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , <b>2011</b> , 20, 291-8   |     | 32 |
| 292 | Diabetes mellitus among outpatients with COPD attending a university hospital. <i>Acta Diabetologica</i> , <b>2014</b> , 51, 933-40  | 1.2 | 31 |
| 291 | Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , <b>2019</b> , 20, 104                   | 1.8 | 30 |
| 290 | Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. <i>Trends in Pharmacological Sciences</i> , <b>2017</b> , 38, 940-951   | 3.4 | 30 |
| 289 | Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 533-41  | 0.9 | 29 |

|     |   |     |    |
|-----|---|-----|----|
| 288 | Acclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 775-81                        | 0.9 | 29 |
| 287 | Are there pulmonary sequelae in patients recovering from COVID-19?. <i>Respiratory Research</i> , <b>2020</b> , 21, 286   | 1.8 | 29 |
| 286 | The Challenges of Precision Medicine in COPD. <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 345-355  | 1.3 | 28 |
| 285 | Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. <i>European Journal of Pharmacology</i> , <b>2015</b> , 761, 383-90 | 1.6 | 28 |
| 284 | Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2016</b> , 55, 804-814      | 1.5 | 28 |
| 283 | An update on bronchodilators in Phase I and II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 1489-501   | 1.8 | 28 |
| 282 | The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. <i>International Journal of COPD</i> , <b>2017</b> , 12, 3469-3485                       | 0.8 | 27 |
| 281 | Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. <i>Human Genomics</i> , <b>2020</b> , 14, 29   | 1.4 | 27 |
| 280 | Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. <i>Equine Veterinary Journal</i> , <b>2017</b> , 49, 710-717   | 0.6 | 26 |
| 279 | TSLP Inhibitors for Asthma: Current Status and Future Prospects. <i>Drugs</i> , <b>2020</b> , 80, 449-458   | 3.3 | 26 |
| 278 | Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2020</b> , 61, 101899               | 0.8 | 26 |
| 277 | Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , <b>2020</b> , 6, 47-66  | 0.8 | 26 |
| 276 | Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. <i>Drug Safety</i> , <b>2016</b> , 39, 501-8   | 1.1 | 26 |
| 275 | The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , <b>2016</b> , 11, 733-44   | 1.6 | 26 |
| 274 | Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , <b>2016</b> , 76, 1257-1270  | 3.3 | 26 |
| 273 | Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 961-77   | 0.9 | 25 |
| 272 | Acute exacerbations of COPD: risk factors for failure and relapse. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2687-2693   | 0.8 | 25 |
| 271 | Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2009</b> , 22, 478-82                              | 0.8 | 25 |

|     |  |     |    |
|-----|--|-----|----|
| 270 | Treating systemic effects of COPD. <i>Trends in Pharmacological Sciences</i> , <b>2007</b> , 28, 544-50  | 3.4 | 25 |
| 269 | Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. <i>Respiratory Medicine</i> , <b>2008</b> , 102, 321-7   | 1.2 | 24 |
| 268 | Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 1150-1163        | 2   | 24 |
| 267 | Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?. <i>Drugs</i> , <b>2014</b> , 74, 1983-92   | 3.3 | 23 |
| 266 | Inhaled corticosteroids for chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2489-99  | 0.9 | 23 |
| 265 | Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGLubeta69. <i>Respiratory Research</i> , <b>2005</b> , 6, 94 | 1.8 | 23 |
| 264 | Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. <i>Trends in Pharmacological Sciences</i> , <b>2019</b> , 40, 452-463  | 3.4 | 22 |
| 263 | Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. <i>Drugs</i> , <b>2015</b> , 75, 1575-85   | 3.3 | 22 |
| 262 | Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. <i>COPD Research and Practice</i> , <b>2015</b> , 1,   |     | 22 |
| 261 | Antitrypsin deficiency and chronic respiratory disorders. <i>European Respiratory Review</i> , <b>2020</b> , 29,   | 2.3 | 22 |
| 260 | Comparative effectiveness of drugs for chronic obstructive pulmonary disease. <i>Drugs of Today</i> , <b>2012</b> , 48, 785-94   | 0.5 | 22 |
| 259 | LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. <i>International Journal of COPD</i> , <b>2018</b> , 13, 3115-3130   | 0.8 | 22 |
| 258 | SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <i>European Respiratory Journal</i> , <b>2020</b> , 56,   | 2.9 | 21 |
| 257 | New perspectives in the treatment of idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2008</b> , 2, 75-93  | 1.2 | 21 |
| 256 | SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. <i>Vaccines</i> , <b>2021</b> , 9,  | 3   | 21 |
| 255 | Role of muscarinic antagonists in asthma therapy. <i>Expert Review of Respiratory Medicine</i> , <b>2017</b> , 11, 239-253   |     | 20 |
| 254 | Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. <i>Drugs</i> , <b>2017</b> , 77, 721-732   | 3.3 | 20 |
| 253 | Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Delivery</i> , <b>2020</b> , 17, 635-646   | 2.1 | 20 |

|     |   |     |    |
|-----|---|-----|----|
| 252 | Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. <i>Respiratory Research</i> , <b>2018</b> , 19, 65  | 1.8 | 20 |
| 251 | Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. <i>Respiratory Medicine</i> , <b>2016</b> , 117, 150-3   | 1.2 | 20 |
| 250 | Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 59, 101841 | 0.8 | 20 |
| 249 | Tiotropium formulations and safety: a network meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , <b>2017</b> , 8, 17-30  | 1.1 | 20 |
| 248 | HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells. <i>European Respiratory Journal</i> , <b>2002</b> , 20, 1174-8  | 2.9 | 20 |
| 247 | Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. <i>Respiratory Medicine</i> , <b>2019</b> , 153, 3-13  | 1.2 | 19 |
| 246 | Pharmacological treatment and current controversies in COPD. <i>F1000Research</i> , <b>2019</b> , 8,  | 1   | 19 |
| 245 | Guidance on nebulization during the current COVID-19 pandemic. <i>Respiratory Medicine</i> , <b>2021</b> , 176, 106236  | 1.2 | 19 |
| 244 | Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 827-833  | 1.8 | 18 |
| 243 | Does bronchoscopy help the diagnosis in COVID-19 infection?. <i>European Respiratory Journal</i> , <b>2020</b> , 56,  | 2.9 | 18 |
| 242 | Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 1417-22   | 1.2 | 18 |
| 241 | Chronic obstructive pulmonary disease and diabetes. <i>COPD Research and Practice</i> , <b>2015</b> , 1,  |     | 18 |
| 240 | Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 561-568  | 1.2 | 18 |
| 239 | Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. <i>Life Sciences</i> , <b>2015</b> , 131, 44-50  | 1.9 | 17 |
| 238 | Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. <i>European Journal of Pharmacology</i> , <b>2017</b> , 812, 147-154  | 1.6 | 17 |
| 237 | Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2014</b> , 50, 493-501                    | 1.5 | 17 |
| 236 | Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. <i>Vaccines</i> , <b>2021</b> , 9,   | 3   | 17 |
| 235 | Serum CA 15-3 is increased in pulmonary fibrosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2009</b> , 26, 54-63   | 0.3 | 17 |



|     |  |     |    |
|-----|--|-----|----|
| 234 | Cardiovascular disease in patients with COPD. <i>Lancet Respiratory Medicine</i> , <b>2015</b> , 3, 593-5  | 8.2 | 16 |
| 233 | Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1019-25       | 1.2 | 16 |
| 232 | Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 40, 34-38  | 1.2 | 16 |
| 231 | The effect of indacaterol during an acute exacerbation of COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2013</b> , 26, 630-4   | 0.8 | 16 |
| 230 | Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 526-532 | 0.5 | 16 |
| 229 | Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 693-708  | 1.2 | 16 |
| 228 | Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. <i>Current Opinion in Pharmacology</i> , <b>2012</b> , 12, 300-8   | 1.2 | 15 |
| 227 | Metabolic syndrome and risk of pulmonary involvement. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 47-51   | 1.2 | 15 |
| 226 | The impact of comorbidities on severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2020</b> , 26, 47-55   | 1.1 | 15 |
| 225 | Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 143-152                               | 1.2 | 15 |
| 224 | Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2019</b> , 156, 78-84   | 1.2 | 14 |
| 223 | Novel glucocorticoid receptor agonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1473-82  | 1.8 | 14 |
| 222 | Impact of doxofylline in COPD: A pairwise meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 51, 1-9  | 0.8 | 14 |
| 221 | Umeclidinium for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2014</b> , 8, 665-71  | 1.2 | 14 |
| 220 | Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2005</b> , 129, 73-9                                    | 0.3 | 14 |
| 219 | Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. <i>Respiratory Medicine</i> , <b>2020</b> , 171, 106114   | 1.2 | 14 |
| 218 | The future of bronchodilation: looking for new classes of bronchodilators. <i>European Respiratory Review</i> , <b>2019</b> , 28,  | 2.3 | 14 |
| 217 | A potential role of triple therapy for asthma patients. <i>Expert Review of Respiratory Medicine</i> , <b>2019</b> , 13, 1079-1085   | 1.2 | 13 |



|     |  |     |    |
|-----|--|-----|----|
| 216 | Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , <b>2019</b> , 154, 86-92   | 1.2 | 13 |
| 215 | QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1079-90   | 0.9 | 13 |
| 214 | How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 435-446   | 1.2 | 13 |
| 213 | Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 33, 1-10  | 0.8 | 13 |
| 212 | Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. <i>European Respiratory Journal</i> , <b>2021</b> , 58,   | 2.9 | 13 |
| 211 | Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 185-194   | 0.8 | 13 |
| 210 | Influence of ethnicity on response to asthma drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 1089-97  | 1.2 | 12 |
| 209 | Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. <i>Clinical and Molecular Allergy</i> , <b>2018</b> , 16, 3  | 1.1 | 12 |
| 208 | Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 848-53   | 1.2 | 12 |
| 207 | Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 737-750   | 0.9 | 12 |
| 206 | Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2019</b> , 28, 744-750   | 0.4 | 12 |
| 205 | Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2019</b> , 16, 215-226                            | 0.5 | 11 |
| 204 | N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. <i>Biomedicine and Pharmacotherapy</i> , <b>2018</b> , 103, 1-8  | 2.3 | 11 |
| 203 | An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. <i>International Journal of Mycobacteriology</i> , <b>2016</b> , 5, 244-7 | 0.2 | 11 |
| 202 | Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. <i>EBioMedicine</i> , <b>2017</b> , 19, 14-15  | 2.7 | 10 |
| 201 | Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 56, 39-50   | 0.8 | 10 |
| 200 | Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 529-39  | 1.3 | 10 |
| 199 | Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 429-435  | 0.9 | 10 |

|     |   |     |    |
|-----|---|-----|----|
| 198 | Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 573-581   | 1.8 | 10 |
| 197 | Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2009</b> , 64, 1389-90 <sup>2.2</sup>   |     | 10 |
| 196 | Thoracoscopic reduction pneumoplasty for severe emphysema: do pleural adhesions affect outcome?. <i>Thoracic and Cardiovascular Surgeon</i> , <b>1999</b> , 47, 288-92  | 0.4 | 10 |
| 195 | Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,  | 1.5 | 10 |
| 194 | Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis. <i>Equine Veterinary Journal</i> , <b>2018</b> , 50, 594-601  | 0.6 | 9  |
| 193 | A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 2014-21  | 1.2 | 9  |
| 192 | Advances with glucocorticoids in the treatment of asthma: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2305-2316  | 0.9 | 9  |
| 191 | LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. <i>Evidence-Based Medicine</i> , <b>2016</b> , 21, 222   |     | 9  |
| 190 | Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa588   | 0.3 | 9  |
| 189 | Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. <i>Drug Safety</i> , <b>2021</b> , 44, 273-290  | 1.1 | 9  |
| 188 | Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. <i>European Journal of Pharmacology</i> , <b>2018</b> , 832, 114-119  | 1.6 | 9  |
| 187 | Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2016</b> , 48, 61-4 | 0.5 | 9  |
| 186 | Bronchodilator therapy for chronic cough. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 47, 88-92  | 0.8 | 8  |
| 185 | Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 44, 83-87   | 0.8 | 8  |
| 184 | Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 50, 28-37  | 0.8 | 8  |
| 183 | Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 239-245  | 1.2 | 8  |
| 182 | The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 589-596   | 0.9 | 8  |
| 181 | An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 43-54  | 1.2 | 8  |

|     |   |     |   |
|-----|---|-----|---|
| 180 | Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 977-88  | 0.9 | 8 |
| 179 | Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 58, 101828  | 0.8 | 8 |
| 178 | Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. <i>Molecular Diagnosis and Therapy</i> , <b>2019</b> , 23, 603-614   | 1.3 | 8 |
| 177 | Anaphylaxis and intimate behaviour. <i>Current Opinion in Allergy and Clinical Immunology</i> , <b>2017</b> , 17, 350-355.8   |     | 8 |
| 176 | Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 641-647  | 0.5 | 8 |
| 175 | Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 35-41  | 1.3 | 8 |
| 174 | Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 107-11  | 1.2 | 8 |
| 173 | Unilateral thoroscopic reduction pneumoplasty for asymmetric emphysema. <i>European Journal of Cardio-thoracic Surgery</i> , <b>1998</b> , 14, 33-9   | 0.6 | 8 |
| 172 | Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. <i>Drugs</i> , <b>2020</b> , 80, 1799-1809  | 3.3 | 8 |
| 171 | Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. <i>Heliyon</i> , <b>2020</b> , 6, e05143  | 1.3 | 8 |
| 170 | Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review. <i>Journal of Experimental Pharmacology</i> , <b>2020</b> , 12, 233-254   | 1.3 | 8 |
| 169 | Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 4750-4765   | 2   | 8 |
| 168 | The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. <i>BioMed Research International</i> , <b>2016</b> , 2016, 4547953   | 0.9 | 8 |
| 167 | Inhaled long-acting muscarinic antagonists in asthma - A narrative review. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 85, 14-22   | 1.1 | 8 |
| 166 | Bronchodilators in subjects with asthma-related comorbidities. <i>Respiratory Medicine</i> , <b>2019</b> , 151, 43-48   | 1.2 | 7 |
| 165 | Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study. <i>Risk Management and Healthcare Policy</i> , <b>2020</b> , 13, 43-53  | 1   | 7 |
| 164 | Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , <b>2018</b> , 41, 546-554 | 0.3 | 7 |
| 163 | The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators. <i>Pharmacological Research</i> , <b>2016</b> , 111, 659-667  | 2.5 | 7 |

|     |  |     |   |
|-----|--|-----|---|
| 162 | Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2013</b> , 26, 156-7                              | 0.8 | 7 |
| 161 | Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. <i>Expert Opinion on Drug Discovery</i> , <b>2014</b> , 9, 595-607  | 1.6 | 7 |
| 160 | The complex care of severe emphysema: role of awake lung volume reduction surgery. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 108  | 0.8 | 7 |
| 159 | New treatments for COPD in the elderly. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 5968-82   | 1   | 7 |
| 158 | Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2019</b> , 13, 1753466619888128            | 1.2 | 7 |
| 157 | Happy hypoxemia, or blunted ventilation?. <i>Respiratory Research</i> , <b>2021</b> , 22, 4  | 1.8 | 7 |
| 156 | Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 1101-1111  | 1.2 | 7 |
| 155 | Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , <b>2021</b> , 187, 106569   | 1.2 | 7 |
| 154 | An update on the pharmacotherapeutic management of lower respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 973-988  | 0.9 | 6 |
| 153 | Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. <i>Advances in Therapy</i> , <b>2019</b> , 36, 3291-3298  | 1.1 | 6 |
| 152 | Ultra-LABAs for the treatment of asthma. <i>Respiratory Medicine</i> , <b>2019</b> , 156, 47-52  | 1.2 | 6 |
| 151 | Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 49, 88-94  | 0.8 | 6 |
| 150 | Is ICS-LAMA an alternative option to treat patients with COPD?. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 316-317  | 8.2 | 6 |
| 149 | Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 791-3 | 1.5 | 6 |
| 148 | Onset of action of budesonide/formoterol Spiromax(□) compared with budesonide/formoterol Turbuhaler(□) in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 39, 48-53                 | 0.8 | 6 |
| 147 | Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. <i>Multidisciplinary Respiratory Medicine</i> , <b>2019</b> , 14, 25   | 0.6 | 6 |
| 146 | Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 1643-1646                   | 1.5 | 6 |
| 145 | Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 59, 101855                                  | 0.8 | 6 |

|     |   |     |   |
|-----|---|-----|---|
| 144 | Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting $\beta$ Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. <i>Pulmonary Therapy</i> , <b>2019</b> , 5, 117-126                    | 0.8 | 6 |
| 143 | Indacaterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 107-15   | 0.9 | 6 |
| 142 | A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2009</b> , 22, 522-5 | 0.8 | 6 |
| 141 | Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. <i>Drugs of Today</i> , <b>2015</b> , 51, 469-78   | 0.5 | 6 |
| 140 | Benralizumab for the treatment of asthma. <i>Drugs of Today</i> , <b>2017</b> , 53, 633-645   | 0.5 | 6 |
| 139 | Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. <i>Journal of Experimental Pharmacology</i> , <b>2020</b> , 12, 559-574  | 1.3 | 6 |
| 138 | Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. <i>World Allergy Organization Journal</i> , <b>2019</b> , 12, 100081  | 1.4 | 6 |
| 137 | Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, 3704-3710  | 0.6 | 6 |
| 136 | Prospects for severe asthma treatment. <i>Current Opinion in Pharmacology</i> , <b>2021</b> , 56, 52-60   | 1.2 | 6 |
| 135 | The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. <i>International Journal of COPD</i> , <b>2021</b> , 16, 257-279   | 0.8 | 6 |
| 134 | Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. <i>Lung</i> , <b>2018</b> , 196, 707-713   | 1.2 | 6 |
| 133 | Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. <i>European Respiratory Journal</i> , <b>2017</b> , 49,                           | 2.9 | 5 |
| 132 | Monoclonal antibodies in severe asthma: is it worth it?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 517-520  | 1.2 | 5 |
| 131 | Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1657-1658   | 3   | 5 |
| 130 | Day and Night Control of COPD and Role of Pharmacotherapy: A Review. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1269-1285   | 0.8 | 5 |
| 129 | Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?. <i>Human Vaccines and Immunotherapeutics</i> , <b>2018</b> , 14, 1438-1441                      | 1.4 | 5 |
| 128 | Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 307-13  | 1.2 | 5 |
| 127 | Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in real life?. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2018</b> , 50, 283-285                       | 0.5 | 5 |

|     |  |     |   |
|-----|--|-----|---|
| 126 | Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 977-990   | 1.3 | 5 |
| 125 | Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19. <i>Diabetes Care</i> , <b>2021</b> , 44, 2149-2157  | 3.9 | 5 |
| 124 | Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life?. <i>Allergologia Et Immunopathologia</i> , <b>2016</b> , 44, 387-8  | 0.5 | 5 |
| 123 | Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection?. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1621-2   | 3   | 5 |
| 122 | Treatable Mechanisms in Asthma. <i>Molecular Diagnosis and Therapy</i> , <b>2021</b> , 25, 111-121   | 1.3 | 5 |
| 121 | Disease awareness in patients with COPD: measurement and extent. <i>International Journal of COPD</i> , <b>2019</b> , 14, 1-11   | 0.8 | 5 |
| 120 | Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 535   | 1.5 | 4 |
| 119 | Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 833-835  | 0.9 | 4 |
| 118 | The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Clinical Respiratory Journal</i> , <b>2019</b> , 13, 166-173  | 0.5 | 4 |
| 117 | The role of triple therapy in the management of COPD. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 865-874  | 1.3 | 4 |
| 116 | A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 509-517  | 0.9 | 4 |
| 115 | Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2018</b> , 15, 310-311  | 0.5 | 4 |
| 114 | Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. <i>Respiration</i> , <b>2018</b> , 96, 543-551   | 0.9 | 4 |
| 113 | Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2019</b> , 11, e2019065 | 0.8 | 4 |
| 112 | Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 579-581   | 1.2 | 4 |
| 111 | Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. <i>Neurological Sciences</i> , <b>2020</b> , 41, 2671-2674   | 0.8 | 4 |
| 110 | New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , <b>2021</b> , 13, 291-302  | 1.3 | 4 |
| 109 | Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified?. <i>Journal of Asthma</i> , <b>2016</b> , 53, 879-81   | 0.5 | 4 |



|     |  |     |   |
|-----|--|-----|---|
| 108 | Depressive and anxiety symptoms in patients with SARS-CoV2 infection. <i>Journal of Affective Disorders</i> , <b>2021</b> , 278, 339-340   | 2   | 4 |
| 107 | Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 611-620   | 0.9 | 4 |
| 106 | Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , <b>2021</b> , 18, 891-906  | 2.1 | 4 |
| 105 | Incidence of pneumomediastinum in COVID-19: A single-center comparison between 1st and 2nd wave. <i>Respiratory Investigation</i> , <b>2021</b> , 59, 661-665  | 0.7 | 4 |
| 104 | Serum- and Glucocorticoid-Inducible Kinase 1 Delay the Onset of Endothelial Senescence by Directly Interacting with Human Telomerase Reverse Transcriptase. <i>Rejuvenation Research</i> , <b>2016</b> , 19, 79-89   | 0.7 | 3 |
| 103 | Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 873                     | 1.5 | 3 |
| 102 | Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. <i>Respiratory Medicine</i> , <b>2019</b> , 153, 68-75   | 1.2 | 3 |
| 101 | What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. <i>Respiratory Medicine</i> , <b>2020</b> , 166, 105937   | 1.2 | 3 |
| 100 | How many systemic reactions to skin prick tests could be preventable in defined conditions?. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2016</b> , 116, 174  | 0.9 | 3 |
| 99  | Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. <i>Journal of Comparative Effectiveness Research</i> , <b>2017</b> , 6, 627-636   | 0.6 | 3 |
| 98  | In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV than long-acting beta-agonists plus inhaled corticosteroids. <i>Evidence-Based Medicine</i> , <b>2017</b> , 22, 183-184 |     | 3 |
| 97  | What Could the Role of Can f 5 Allergen Be in Dog-Sensitized Patients in "Real Life"?. <i>Journal of Investigational Allergology and Clinical Immunology</i> , <b>2017</b> , 27, 397-398   | 0.6 | 3 |
| 96  | The clinical use of regenerative therapy in COPD. <i>International Journal of COPD</i> , <b>2014</b> , 9, 1389-96  | 0.8 | 3 |
| 95  | Ergonomical Assessment of Three-Dimensional Versus Two-Dimensional Thoracoscopic Lobectomy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , <b>2020</b> , 32, 1089-1096   | 0.2 | 3 |
| 94  | Pharmacological management of adult patients with acute respiratory distress syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2169-2183  | 0.9 | 3 |
| 93  | Sex differences in COPD management. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 323-332  | 1.3 | 3 |
| 92  | Staged unilateral lung volume reduction surgery: from mini-invasive to minimalist treatment strategies. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S2754-S2762   | 0.6 | 3 |
| 91  | Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 2043-2053  | 0.9 | 3 |



|    |  |     |   |
|----|--|-----|---|
| 90 | Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. <i>Pharmacological Research</i> , <b>2021</b> , 172, 105801   | 2.5 | 3 |
| 89 | Indacaterol/Glycopyrronium Combination for COPD. <i>Pulmonary Therapy</i> , <b>2017</b> , 3, 45-57   | 0.8 | 2 |
| 88 | A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 2399-2401                     | 1.5 | 2 |
| 87 | Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 49, 20-26                       | 0.8 | 2 |
| 86 | Dog allergen immunotherapy and allergy to furry animals. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2016</b> , 116, 590  | 0.9 | 2 |
| 85 | Emerging antibacterial and antiviral drugs for treating respiratory tract infections. <i>Expert Opinion on Emerging Drugs</i> , <b>2018</b> , 23, 185-199  | 0.9 | 2 |
| 84 | Beyond Dual Bronchodilation - Triple Therapy, When and Why.. <i>International Journal of COPD</i> , <b>2022</b> , 17, 165-180  | 0.8 | 2 |
| 83 | First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?. <i>Microorganisms</i> , <b>2022</b> , 10, | 1.7 | 2 |
| 82 | As needed therapies in mild to severe asthma: a systematic review and network meta-analysis <b>2020</b>  |     | 2 |
| 81 | Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. <i>US Respiratory &amp; Pulmonary Diseases</i> , <b>2020</b> , 5, 18  | 0   | 2 |
| 80 | Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2019</b> , 51,  | 0.5 | 2 |
| 79 | Use of mucolytics in COPD: A Delphi consensus study. <i>Respiratory Medicine</i> , <b>2020</b> , 175, 106190   | 1.2 | 2 |
| 78 | The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,   | 1.5 | 2 |
| 77 | Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2020</b> , 13, 261-271   | 0.4 | 2 |
| 76 | Mortality in ETHOS: A Question of "Power". <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 926-927  | 2.5 | 2 |
| 75 | Quasibar minimalist lung volume reduction surgery. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2021</b> , 60, 598-606  | 0.6 | 2 |
| 74 | Lessons from peculiar cases of anaphylaxis: why allergists should be prepared for the unexpected. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2021</b> ,  | 0.5 | 2 |
| 73 | Step-up and step-down approaches in the treatment of asthma. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1159-1168  | 1.2 | 2 |

|    |   |     |   |
|----|---|-----|---|
| 72 | Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. <i>Monaldi Archives for Chest Disease</i> , <b>2020</b> , 90, | 0.7 | 2 |
| 71 | Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 59-70  | 1.2 | 2 |
| 70 | Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , <b>2021</b> , 100, 291-297   | 0.9 | 2 |
| 69 | Drug interaction and chronic obstructive respiratory disorders.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2021</b> , 2, 100009   | 1.1 | 2 |
| 68 | Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma. <i>Clinical Respiratory Journal</i> , <b>2021</b> , 15, 237-243  | 0.5 | 2 |
| 67 | Use of Thiols in the Treatment of COVID-19: Current Evidence. <i>Lung</i> , <b>2021</b> , 199, 335-343  | 1.2 | 2 |
| 66 | Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2021</b> , 69, 102050                                       | 0.8 | 2 |
| 65 | An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. <i>Biologics: Targets and Therapy</i> , <b>2021</b> , 15, 363-374  | 1   | 2 |
| 64 | The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review. <i>Biomedicines</i> , <b>2021</b> , 9,  | 1.6 | 2 |
| 63 | SMART for the treatment of asthma: A network meta-analysis of real-world evidence. <i>Respiratory Medicine</i> , <b>2021</b> , 188, 106611  | 1.2 | 2 |
| 62 | Response. <i>Chest</i> , <b>2019</b> , 155, 1079-1080   | 1.2 | 1 |
| 61 | Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 723-738   | 1.8 | 1 |
| 60 | Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. <i>Expert Review of Respiratory Medicine</i> , <b>2020</b> , 14, 621-635  | 1.2 | 1 |
| 59 | Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. <i>BMJ Evidence-Based Medicine</i> , <b>2018</b> , 23, 183-184  | 1   | 1 |
| 58 | Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2004</b> , 127, 1212-4   | 0.3 | 1 |
| 57 | Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies.. <i>Journal of Experimental Pharmacology</i> , <b>2022</b> , 14, 1-5   | 1.3 | 1 |
| 56 | Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. <i>Drugs</i> , <b>2021</b> , 1   | 3.3 | 1 |
| 55 | The possible concomitant use of aeroallergen and food panels for skin prick testing might enhance the risk of generalized allergic reactions in children. <i>Turkish Journal of Pediatrics</i> , <b>2019</b> , 61, 815-816                                | 0.2 | 1 |

|    |  |     |   |
|----|--|-----|---|
| 54 | Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. <i>Monaldi Archives for Chest Disease</i> , <b>2021</b> ,   | 0.7 | 1 |
| 53 | A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2020</b> , 60, 101883   | 0.8 | 1 |
| 52 | Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis. <i>Respiratory Medicine and Research</i> , <b>2020</b> , 78, 100791  | 0.3 | 1 |
| 51 | Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1. <i>Journal of Clinical Sleep Medicine</i> , <b>2021</b> , 17, 2383-2391   | 0.8 | 1 |
| 50 | Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens. <i>Upsala Journal of Medical Sciences</i> , <b>2016</b> , 121, 196-7                          | 1.1 | 1 |
| 49 | Radiological pitfalls associated with the diagnosis of usual interstitial pneumonia pattern on high-resolution computed tomography and associated findings: experience from a single Italian center. <i>Acta Radiologica</i> , <b>2021</b> , 62, 619-627 | 0.4 | 1 |
| 48 | Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow milk aspiration. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2021</b> , 2, 100010                     | 1.1 | 1 |
| 47 | Mepolizumab Effectiveness and Allergic Status in Real Life. <i>International Archives of Allergy and Immunology</i> , <b>2021</b> , 182, 311-318   | 0.8 | 1 |
| 46 | Electrocardiographic modifications and cardiac involvement in COVID-19 patients: results from an Italian cohort. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 190-196   | 0.6 | 1 |
| 45 | Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 103-112  | 1.2 | 1 |
| 44 | Anxiety and asthma in youth. Is a stress-induced increased cholinergic tone the possible link?. <i>Pediatric Pulmonology</i> , <b>2018</b> , 53, 128-129   | 0.7 | 1 |
| 43 | Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2018</b> , 121, 512-513  | 0.9 | 1 |
| 42 | LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. <i>Respiration</i> , <b>2018</b> , 96, 370-381  | 0.9 | 1 |
| 41 | Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,  | 1.9 | 1 |
| 40 | Face masks during COVID-19 pandemic lockdown and self-reported seasonal allergic rhinitis symptoms. <i>Rhinology</i> , <b>2021</b> , 59, 481-484   | 1.9 | 1 |
| 39 | Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1473-1481        | 1.2 | 1 |
| 38 | Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2017</b> , 49, 92-96                     | 0.5 | 1 |
| 37 | Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. <i>New Microbiologica</i> , <b>2017</b> , 40, 107-112  | 0.4 | 1 |

|    |  |     |   |
|----|--|-----|---|
| 36 | The future of inhalation therapy in chronic obstructive pulmonary disease.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2022</b> , 3, 100092   | 1.1 | 1 |
| 35 | Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma.. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2022</b> , 102125                                     | 0.8 | 1 |
| 34 | Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile.. <i>Journal of Asthma and Allergy</i> , <b>2022</b> , 15, 565-577   | 0.9 | 1 |
| 33 | Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. <i>Cells</i> , <b>2022</b> , 11, 1797  | 2   | 1 |
| 32 | An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. <i>Expert Opinion on Pharmacotherapy</i> , 1-12   | 0.9 | 1 |
| 31 | Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2020</b> , 17, 215-223 | 0.5 | 0 |
| 30 | Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link?. <i>Respirology</i> , <b>2016</b> , 21, 1496-1497  | 1   | 0 |
| 29 | Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy). <i>European Annals of Allergy and Clinical Immunology</i> , <b>2020</b> , 52, 230-234  | 0.5 | 0 |
| 28 | Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. <i>Respiratory Medicine</i> , <b>2021</b> , 189, 106639   | 1.2 | 0 |
| 27 | Management of COPD patients during COVID: difficulties and experiences. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1025-1033   | 1.2 | 0 |
| 26 | Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 1-9   | 1.2 | 0 |
| 25 | Current long-acting muscarinic antagonists for the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2343-2357   | 0.9 | 0 |
| 24 | Which LABA/LAMA should be chosen in COPD patients in real life?. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2021</b> , 71, 102076   | 0.8 | 0 |
| 23 | Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 1093-1094  | 1.5 |   |
| 22 | Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?. <i>International Archives of Allergy and Immunology</i> , <b>2019</b> , 180, 142-143   | 0.8 |   |
| 21 | CD71 Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1444-1446   | 2.5 |   |
| 20 | Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals?. <i>Journal of Occupational Health</i> , <b>2017</b> , 59, 310-311   | 0.7 |   |
| 19 | Immunogenesis of Lung Granulomatosis: New Acquisitions. <i>International Journal of Immunopathology and Pharmacology</i> , <b>1996</b> , 9, 77-77  | 0.9 |   |

|    |  |     |
|----|--|-----|
| 18 | Use of face masks and allergic rhinitis from ragweed: why mention only total pollen count and not air pollution levels?. <i>International Forum of Allergy and Rhinology</i> , <b>2021</b> ,   | 1.4 |
| 17 | Sleep and wake impairment in patients with SARS-CoV2 infection. <i>Sleep Medicine</i> , <b>2020</b> , 73, 177-178  | 1.3 |
| 16 | Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 112   | 0.8 |
| 15 | Systemic pharmacotherapy <b>2019</b> , 215-222   |     |
| 14 | Critical interpretation of pairwise and network meta-analysis of randomized respiratory clinical trials. <i>AboutOpen</i> , <b>2019</b> , 6, 55-61   | 0.1 |
| 13 | Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations. <i>Journal of Investigational Allergology and Clinical Immunology</i> , <b>2019</b> , 29, 472-473  | 0.6 |
| 12 | Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ?. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2020</b> , 52, 190-192   | 0.5 |
| 11 | Cardiovascular disease in COPD <b>2020</b> , 47-65   |     |
| 10 | Occupational allergy to horse allergens: More than exposure to horses!. <i>International Journal of Occupational Medicine and Environmental Health</i> , <b>2016</b> , 29, 721-3   | 0.6 |
| 9  | Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 943-945   | 0.9 |
| 8  | Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?. <i>Journal of Investigational Allergology and Clinical Immunology</i> , <b>2016</b> , 26, 403-405  | 0.6 |
| 7  | Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis. <i>Acta Radiologica</i> , <b>2020</b> , 61, 204-218  | 0.4 |
| 6  | Can placebo challenge test (inducing a "nocebo effect") be a suitable model to assess stress-induced bronchial obstruction? Suggestions from the multidisciplinary Working Groups "Stress-Asthma" and "AAIITO Regione Campania". <i>European Annals of Allergy and Clinical Immunology</i> , <b>2021</b> , 53, 284-287 | 0.5 |
| 5  | Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 1808-1809   | 1.5 |
| 4  | Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?. <i>US Respiratory &amp; Pulmonary Diseases</i> , <b>2021</b> , 6, 31  | 0   |
| 3  | Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. <i>BMC Pulmonary Medicine</i> , <b>2021</b> , 21, 396   | 1   |
| 2  | Use of face masks and allergic nasal symptoms: Why not mention pollen count and air pollution data?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , <b>2021</b> , 103363   | 0.7 |
| 1  | Seasonal monitoring of serum IgE and blood eosinophil variability may lead to a better severe asthma phenotyping and to a correct biologic prescription. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2020</b> , 34, 315-318  | 0.3 |

